Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Review uri icon

Overview

abstract

  • Clinical data and models of human disease indicate that androgen receptor (AR) activity is essential for prostate cancer development, growth, and progression. The dependence of prostatic adenocarcinoma on AR signaling at all stages of disease has thereby been exploited in the treatment of disseminated tumors, for which ablation of AR function is the goal of first-line therapy. Although these strategies are initially effective, recurrent tumors arise with restored AR activity, and no durable treatment has yet been identified to combat this stage of disease. New insights into AR regulation and the mechanisms underlying resurgent AR activity have provided fertile ground for the development of novel strategies to more effectively inhibit receptor activity and prolong the transition to therapeutic failure.

publication date

  • July 28, 2009

Research

keywords

  • Prostatic Neoplasms
  • Receptors, Androgen

Identity

PubMed Central ID

  • PMC2842118

Scopus Document Identifier

  • 68049140791

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-08-2660

PubMed ID

  • 19638458

Additional Document Info

volume

  • 15

issue

  • 15